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Abstract
Background: A novel approach to determine the effect of a treatment is to calculate the delay of event, which estimates
the gain of event-free time. The aim of this study was to estimate gains in event-free time for stroke or systemic
embolism, death, bleeding events, and the composite of these events, in patients with atrial fibrillation randomized to
either warfarin or apixaban in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial
Fibrillation trial (ARISTOTLE).
Design: The ARISTOTLE study was a randomized double-blind trial comparing apixaban with warfarin.
Methods: Laplace regression was used to estimate the delay in time to the outcomes between the apixaban and the
warfarin group in 6, 12, 18 and 22 months of follow-up.
Results: The gain in event-free time for apixaban versus warfarin was 181 (95% confidence interval 76 to 287) days for
stroke or systemic embolism and 55 (–4 to 114) days for death after 22 months of follow-up. The corresponding gains in
event-free times for major and intracranial bleeding were 206 (130 to 281) and 392 (249 to 535) days, respectively. The
overall gain for the composite of all these events was a gain of 116 (60 to 171) days.
Conclusions: In patients with atrial fibrillation, 22 months of treatment with apixaban, as compared with warfarin,
provided gains of approximately 6 months in event-free time for stroke or systemic embolism, 7 months for major
bleeding and 13 months for intracranial bleeding.
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Introduction
Atrial fibrillation is the most common clinically import-
ant arrhythmia with a prevalence above 10% in those
above the age of 80 years.1 Atrial fibrillation is asso-
ciated with an increased risk of stroke, heart failure and
premature mortality.2 International guidelines recom-
mend preventive treatment with oral anticoagulation
that substantially reduces the risk of stroke and mor-
tality but simultaneously increases the risk of bleeding,
including intracranial bleeding.3,4
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(ARISTOTLE) was a randomized controlled multicen-
tre trial that showed that apixaban, a non-vitamin K
antagonist oral anticoagulant (NOAC), compared with
warfarin, reduced the risk of stroke, major bleeding and
death in patients with atrial fibrillation and at least one
additional risk factor for stroke.5 As is conventional,
the effect of apixaban in ARISTOTLE was assessed
using Cox proportional-hazards modelling, with the
treatment effect expressed as a hazard ratio.5
Although well established, this method has some limi-
tations, and in providing an estimate of relative
risk-reduction may not, alone, be sufficient for clinical
decision making.6–10 Alternative methods have been
suggested to complement hazard ratios derived from
proportional-hazards modelling,11,12 one of them
being the novel ‘delay of event’ measure, which esti-
mates treatment effects as event-free time gained on
the time scale regarding a certain outcome.12,13
The aim of this study was to estimate effects of apix-
aban versus warfarin in the ARISTOTLE trial as gains
in event-free time estimated by delay of events, for stroke
or systemic embolism, death and bleeding events or the
composite of these events as another measure of treat-
ment effect. Since absolute gains by treatment generally
depend on the patient’s initial risk, gain in event-free
time was also assessed in subgroups based on age,
prior stroke or systemic embolism and prior warfarin
treatment, and by the quality of the medical centre’s
therapeutic range for warfarin treatment.
Methods
The ARISTOTLE trial design and participants
Details of the ARISTOTLE trial have been pub-
lished.5,14 Briefly, ARISTOTLE was a double-blind,
double-dummy, randomized clinical trial that compared
apixaban with warfarin in 18,201 patients, recruited
between 2006 and 2010 at 1034 centres in 39 countries.
The patients included in the ARISTOTLE trial had
atrial fibrillation and one or more additional risk factor
for stroke including: age 75 years; history of prior
stroke, history of transient ischaemic attack, or sys-
temic embolism; symptomatic heart failure within
3 months or systolic dysfunction with a left ventricular
ejection fraction 40%; diabetes mellitus; and hyper-
tension requiring pharmacological treatment.
Exclusion criteria were atrial fibrillation due to a revers-
ible cause, moderate or severe mitral stenosis, condi-
tions other than atrial fibrillation that required
anticoagulation, stroke within the previous seven
days, required aspirin >165mg/day or both aspirin
and clopidogrel, and severe renal insufficiency (serum
creatinine level of >2.5mg/dl or calculated creatinine
clearance of <25ml/min) among others.14
Patients who met the inclusion criteria were ran-
domly assigned (1:1) to receive either apixaban (5mg
twice daily) or warfarin with a treatment target of inter-
national normalized ratio (INR) 2.0–3.0. The apixaban
dose was reduced to 2.5mg twice daily for patients with
two of the three criteria older age, higher creatinine
level and lower body weight. Randomization was stra-
tified according to whether patients had received war-
farin previously or not.
Outcomes
This study’s primary outcome was the event of
stroke (ischaemic or haemorrhagic) or systemic embol-
ism, the same as in the original ARISTOTLE trial.5
A priori defined secondary outcomes were death from
any cause and a composite of stroke, systemic embol-
ism, death or major bleeding. Safety outcomes were
major and intracranial bleeding according to
International Society on Thrombosis and Haemostasis
criteria.15
Statistical analyses
Delay of events was calculated as differences in time-to-
event between the apixaban and warfarin groups at
equal proportions of events occurred (percentiles).12,13
Given a specific percentile, the delay of event expresses
the treatment benefit in terms of a delayed event, that
is, the event-free time that is attributed to the superior
treatment on the time scale. When using this approach,
the proportions of event in each group are fixed and the
time period is the estimated outcome.16 Delay of events
and corresponding 95% confidence intervals (CIs) in
days were estimated by fitting Laplace regression
models. Laplace regression is a type of quantile regres-
sion suitable for censored data.17 Quantile regression
has advantages such as no distributional assumptions
about the regression error term need to be made; its
inference is invariant to monotone transformations of
the outcome variable; and it permits thorough inference
on the entire shape of the conditional distribution and
not just the mean.18
Delay of events and corresponding percentiles were
estimated at four time points: 6 months, 12 months,
18 months and 22 months (median length of follow-
up) into the study period. At each time point the
event rate in per cent (percentile) in the apixaban
group was used as the base for delay of event estima-
tions. Interaction tests were performed for treatment
groups and subgroups. Results were also graphically
reported over the full follow-up by plotting the delay
time in the apixaban group versus the warfarin group.
The analyses were performed with the Laplace package
of the statistical software R.17
2 European Journal of Preventive Cardiology 0(00)
Subgroups
Analyses of delay of events due to treatment were also
performed in a priori defined subgroups of patients <75
years or 75 years, with or without prior stroke or
systemic embolism, and those having used warfarin or
another vitamin K antagonist >30 consecutive days or
not having received warfarin for more than 30 days
previously. Each trial centre’s quality of warfarin treat-
ment was assessed using a linear mixed model as the
median predicted centre’s average time in therapeutic
range (cTTR) in warfarin-treated patients, as previ-
ously described.19 Based on the results, participants
were then dichotomized into those treated at centres
with cTTR at or below the median, or above median
cTTR. For more detailed descriptions of the cTTR
classification, readers are referred to previous
publications.19
Ethical considerations and trial registration
ARISTOTLE was approved by the institutional
review board/ethics committee at each investigative
site and all patients gave written informed consent.
ARISTOTLE is registered with ClinicalTrials.gov,
number NCT00412984.
Results
Among the 18,201 patients that were enrolled in the
ARISTOTLE trial, the median age was 70 years and
12,522 patients (68.8%) were younger than 75 years of
age. Overall, 3523 patients (19.4%) had a history of
stroke or systemic embolism, and 10,376 (57.1%) had
a history of prior warfarin treatment. The median pre-
dicted cTTR for the patients in the warfarin arm was
66.0%, with an interquartile range from 60.0% to
71.2%. The median length of follow-up was 22
months (interquartile range 18–29).
Over a median of 22 months of follow-up, 212
patients (1.27% per year) in the apixaban group devel-
oped stroke or systemic embolism; the corresponding
number in the warfarin group was 265 (1.60% per
year). Death from any cause occurred in 603 patients
(3.52% per year) in the apixaban group, and in 669
patients (3.94% per year) in the warfarin group
(Table 1). Major bleeding occurred in 327 patients
(2.13% per year) in the apixaban group and 462
patients (3.09% per year) in the warfarin group; intra-
cranial bleeding occurred in 52 patients (0.33% per
year) in the apixaban group and in 122 patients
(0.80% per year) in the warfarin group. The composite
outcome of stroke, systemic embolism, death or major
bleeding occurred in 1009 patients (6.13% per year) in
the apixaban group and in 1168 patients (7.20% per
year) in the warfarin group. T
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Estimate of gain in event-free time in the total
material
The gain in event-free time for stroke or systemic
embolism with apixaban, compared with warfarin,
was 53 (95% CI –30 to 137) days at 6 months, 116
(45 to 187) days at 12 months, 149 (40 to 258) days at
18 months, and 181 (76 to 287) days at 22 months of
follow-up (Table 1 and Figure 1(a)).
The corresponding gains in overall survival time
(death from any cause) were 52 (17 to 87) days after
6 months, 58 (8 to 107) days after 12 months, 57 (–6 to
121) days after 18 months, and 55 (–4 to 114) days after
22 months of follow-up (Table 1 and Figure 1(b)).
The gain in event-free time for major bleeding was
206 (130 to 281) days and for intracranial bleeding the
gain was 392 (249 to 535) days on apixaban, compared
with warfarin, after 22 months (Table 1, Figure 1(c)
and 1(d)).
The gain in event-free time for the composite out-
come of stroke, systemic embolism, death or major
bleeding was 42 (14 to 70) days after 6 months,
86 (43 to 128) days after 12 months, 112 (53 to 171)
days after 18 months, and 116 (60 to 171) days after
22 months, with apixaban compared with warfarin
(Table 1 and Figure 1(e)).
The continuous increase in gains in event-free time
for stroke or systemic embolism, death from any cause,
major and intracranial bleeding, and the composite out-
come are shown in Figure 1 with the corresponding
cumulative event rates for each of these outcomes. To
clarify the meaning and interpretation of the delay of
event measure, results on the stroke or systemic embol-
ism outcome is highlighted with plotted lines at 12 and
22 months of follow-up in Figure 1(a).
Estimates of gain in event-free time associated with
treatment in subgroups
In patients 75 years of age or older, the gain in event-
free time for stroke or systemic embolism with apixa-
ban, compared with warfarin, was 237 (95% CI 78 to
397) days after 22 months of follow-up; the correspond-
ing number for patients below 75 years of age was 141
(–8 to 290) days (Table 2).
In patients with prior stroke, the gain in event-free time
for stroke or systemic embolism with apixaban was 223
(68 to 379) days after 22 months of follow-up; the corres-
ponding number for patients with no prior stroke was 147
(24–269) days (Table 2).
In patients previously treated with warfarin, the gain
in event-free time for stroke or systemic embolism with
apixaban was 205 (53 to 358) days, and for patients
without previous warfarin treatment the gain was 145
(1 to 288) days, after 22 months of follow-up (Table 2).
The time gain in death from any cause by assignment
to apixaban, as compared with warfarin, was similar
across the subgroups after 22 months of follow-up
(Table 2).
Regarding the safety outcome major bleeding, the
gain in event-free time with apixaban ranged from 93
to 307 days after 22 months of follow-up (Table 3). The
largest numerical difference was related to cTTR, with
larger gains in centres with poorer INR control.
Regarding the safety outcome intracranial bleeding,
the gain in event-free time with apixaban ranged from
320 to 463 days, after 22 months of follow-up, with
similar gains in all subgroups (Table 3). Generally,
there were no treatment by subgroup interactions.
Discussion
We estimated the treatment effects of apixaban, com-
pared with warfarin, on gain in event-free time for
patients with atrial fibrillation. We showed that
22 months’ treatment with apixaban provided gains
of approximately 6 months in event-free time concern-
ing stroke or systemic embolism, 7 months for major
bleeding and 13 months for intracranial bleeding. These
time-based assessments provide an alternative, clinic-
ally relevant and more comprehensible way of describ-
ing the effects of treatments,20–24 in this case the
benefits of apixaban over warfarin for stroke preven-
tion in patients with atrial fibrillation.
The gain in event-free time with apixaban, compared
with warfarin, for stroke or systemic embolism, was
obtained early after treatment initiation and main-
tained thereafter, during the remainder of the follow-
up. The gain in event-free time for major and intracra-
nial bleeding was also continuous and almost linear,
starting directly after treatment initiation and with no
levelling off during follow-up. A delay of mortality
occurred early after treatment start, but this effect
became attenuated over time. It is worth noting that
the aggregated results suggest a temporal diversity in
the incremental benefits and safety of apixaban versus
warfarin. For example, the primary efficacy endpoint
resulted in a delay of about 6 months during
22 months of follow-up, which roughly corresponds
to a relative 27% event-free time prolongation.
However, 12 months of treatment were needed to let
an initial effect emerge. An earlier and sustained delay
was seen in terms of bleeding. The magnitude of gains
in event-free time for major bleeding and, especially,
intracranial bleeding was quite substantial (a relative
event prolongation of about 31% and 59% respect-
ively), given the rather short treatment period.
Because the gains in time free of stroke or systemic
embolism, and major or intracranial bleeding events,
increased continuously during follow-up, it is possible
4 European Journal of Preventive Cardiology 0(00)
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Figure 1. Cumulative incidence in apixaban and warfarin groups, and delay of events associated with apixaban use for (a) stroke or
systemic embolism, (b) death from any cause, (c) major bleeding, (d) intracranial bleeding, (e) composite measure of stroke, systemic
embolism, death or major bleeding.
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that even larger benefits might be observed with longer
duration treatment. The results in this study are con-
trasted by previous studies assessing effects as post-
ponements of events. The effect of the antiplatelet
treatment ticagrelor over clopidogrel in persons with
acute coronary syndrome, with or without ST-segment
elevation, was demonstrated as delays of the evaluated
outcomes ranging from 83 to 98 days over 400-day
follow-up, also with positive, although non-significant,
curve trends for total bleeding and non-coronary artery
bypass grafting-related major bleedings.25 And the
long-term follow-up of FRISC-II, a prospective rando-
mized multicentre trial investigating the effect of early
revascularization compared with a non-invasive
strategy in patients with non-ST-elevation acute coron-
ary syndrome, revealed average postponement, calcu-
lated as the area between mean cumulative count-of-
events curves, of the occurrence of death or next myo-
cardial infarction by an average of about 18 months.26
This present study also investigated outcomes in sub-
groups. For stroke or systemic embolism, the gains in
event-free time were numerically larger for subgroups
with a higher risk of stroke, that is, patients older than
75 years, patients with a history of prior stroke or prior
warfarin treatment and for patients treated at clinic
with poorer cTTR.
It is worth noting that gains in event-free time
are expected to differ for different outcomes.
Table 3. Delay of events associated with apixaban use, as compared with warfarin, for bleeding outcomes and composite measure of
stroke, systemic embolism, death or major bleeding in subgroups.
Major bleeding Intracranial bleeding
Stroke, systemic embolism,
death or major bleeding
Hazard ratio
(95% CI) E (%)a DoE (days) (95% CI) E (%)a DoE (days) (95% CI) E (%)a DoE (days) (95% CI)
Below 75 years of age 0.88 (0.76–1.00) 2.87 174 (46–302) 0.53 345 (149–542) 8.51 102 (23–181)
75 years of age or above 0.91 (0.77–1.10) 5.95 222 (114–330) 0.84 415 (7–823) 14.96 125 (44–207)
No prior stroke or
systemic embolism
0.88 (0.70–1.10) 3.44 214 (117–310) 0.52 355 (181–528) 9.69 121 (54–187)
Prior stroke or
systemic embolism
0.90 (0.80–1.00) 5.35 186 (43–328) 1.11 451 (167–735) 14.05 92 (–9 to 194)
No prior warfarin 0.91 (0.78–1.10) 3.84 229 (88–371) 0.88 320 (97–543) 11.50 121 (36–206)
Prior warfarin 0.88 (0.76–1.00) 3.76 186 (85–287) 0.45 438 (250–626) 9.77 110 (31–189)
Higher cTTR 0.79 (0.79–1.10) 4.54 93 (–11 to 197) 0.50 463 (258–668) 10.14 45 (–40 to 130)
Lower cTTR 0.87 (0.75–1.00) 3.04 307 (183–431) 0.77 324 (61–587) 10.90 178 (96–259)
aEvent in per cent (percentile) reached in the apixaban group at 22 months and measuring point for presented delay of event (DoE) in days.
CI: confidence interval; cTTR: center time in therapeutic range.
Table 2. Delay of events associated with apixaban use, as compared with warfarin, for stroke or systemic embolism and death from
any cause in subgroups.
Stroke or systemic embolism Death from any cause
Hazard ratio (95% CI) E (%)a DoE (days) (95% CI) E (%)a DoE (days) (95% CI)
Below 75 years of age 0.85 (0.67–1.10) 2.02 141 (–8 to 290) 4.75 68 (–7 to 142)
75 years of age or above 0.71 (0.53–0.95) 2.93 237 (78–397) 9.09 49 (–42 to 140)
No prior stroke or systemic embolism 0.83 (0.66–1.00) 1.80 147 (24–269) 5.85 51 (–25 to 128)
Prior stroke or systemic embolism 0.75 (0.56–1.00 4.48 223 (68–379) 7.14 69 (–45 to 183)
No prior warfarin 0.86 (0.67–1.10) 2.91 145 (1–288) 7.04 56 (–41 to 152)
Prior warfarin 0.73 (0.53–0.95) 1.84 205 (53–358) 5.39 59 (–29 to 146)
Higher cTTR 0.79 (0.59–1.10) 1.67 154 (0–308) 5.14 21 (–92 to 134)
Lower cTTR 0.79 (0.79–1.00) 2.94 203 (84–323) 7.07 71 (–5 to 147)
aEvent in per cent (percentile) reached in the apixaban group at 22 months and measuring point for presented delay of event (DoE) in days.
CI: confidence interval; cTTR: center time in therapeutic range.
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Outcomes such as stroke or systemic embolism and
major bleeding might be avoided by a more effective
and safer treatment; however, this is not the case for
the outcomes that are chronically progressive despite
treatment and which cannot be avoided in the long
term, such as death from any cause.27,28 In this study,
the increase in delay regarding mortality levelled off
over the follow-up, and the gains in overall survival
time with apixaban were seen mainly during the first
half of the follow-up period. For example, in the one
third of patients aged 75 years or older, mortality was
higher than in the younger patients and the gain in
survival time shorter, likely because of the competing
risk of causes of death not modifiable by apixaban.
Another difference between estimating effects using
proportional hazards models and the delay of event
approach used in this study is that hazard ratios are
ratios of failure rates between compared groups,
which in essence are a proportional comparison. The
delay of event, on the other hand, is a comparison of
the timing of events in the groups of interest, given
equal event proportions, providing an estimate of the
magnitude of the effect. Importantly, the delay is con-
ditional on the event, meaning that the effect applies
only to those who will develop the event during a time
period without the superior treatment. This is a limita-
tion of the delay of event measure, as it does not present
a measure that directly applies to the whole study popu-
lation, rather only those that would have the event (if
treated with the control therapy). On the other hand,
any preventive treatment could in a given time period
have an effect only in individuals who, if untreated,
would develop an event. Thus, the delay of event is a
complementary estimate of a preventive effect, depict-
ing the magnitude of effect, using a time-based measure,
in those who benefit during the follow-up.
In addition, the individual interpretation of the delay
of event measure is conditional on having experienced
the event at a specific time point, if not treated with a
more effective drug. In this case the individual inter-
pretation of the results would be that the occurrence
of an eventual stroke or a systematic embolism may be
delayed up to approximately 181 days, and major
bleeding delayed up to approximately 206 days,
during treatment with apixaban for 22 months, com-
pared with warfarin. For clinical decision making we
suggest that delay of event be complemented with other
risk information, such as estimates of an individual’s
absolute risk of developing the event of interest.
Guidelines emphasize the importance of adherence for
prescribed NOAC regimens.4,29 Presenting treatment
effects as gains in event-free times and delay of events
might be more understandable for lay people, patients
and clinicians,20–24 such that these measures may have
an educational role in supporting adherence to
treatment. The potential use of the delay of event meas-
ure in decision making remains to be further
investigated.
Conclusion
In patients with atrial fibrillation, 22 months of treat-
ment with apixaban, as compared with warfarin, pro-
vided gains of approximately 6 months in event-free
time for stroke or systemic embolism, 7 months for
major bleeding and 13 months for intracranial bleeding.
These alternative and innovative time-based assess-
ments quantify the magnitude of the benefits of apixa-
ban over warfarin used to prevent stroke and bleeding
events in patients with atrial fibrillation.
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